{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:51:24Z","timestamp":1791661884129,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejca.2026.117450","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:49:25Z","timestamp":1790981365000},"page":"117450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study"],"prefix":"10.1016","volume":"248","author":[{"given":"Celine","family":"Khouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Bibollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassine","family":"Bouchoucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Combarel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Delahousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bourdeaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9979-0297","authenticated-orcid":false,"given":"Arnault","family":"Tauziede-Espariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Metais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Varlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3405-1944","authenticated-orcid":false,"given":"Kevin","family":"Beccaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Blauwblomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lelio","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Benichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulanjalee","family":"Kariyawasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1260-5886","authenticated-orcid":false,"given":"Volodia","family":"Dangouloff-Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Boddaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura","family":"Sellami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Simbozel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Guerrini-Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-3643","authenticated-orcid":false,"given":"Birgit","family":"Geoerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Grill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7159-8869","authenticated-orcid":false,"given":"Samuel","family":"Abbou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"_10","key":"10.1016\/j.ejca.2026.117450_bib1","doi-asserted-by":"crossref","first-page":"x1","DOI":"10.1093\/neuonc\/nou327","article-title":"Alex\u2019s lemonade stand foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007\u20132011","volume":"16","author":"Ostrom","year":"2015","journal-title":"Neuro-Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.117450_bib2","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1227\/NEU.0b013e318214a66e","article-title":"Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group","volume":"68","author":"Wisoff","year":"2011","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.ejca.2026.117450_bib3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3171\/2022.6.PEDS22108","article-title":"Long-term follow-up of surgical intervention pattern in pediatric low-grade gliomas: report from the German SIOP-LGG 2004 cohort","volume":"30","author":"Thomale","year":"2022","journal-title":"J Neurosurg Pediatr"},{"issue":"12","key":"10.1016\/j.ejca.2026.117450_bib4","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/JCO.2011.34.5843","article-title":"Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma","volume":"30","author":"Bouffet","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117450_bib5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejca.2017.04.019","article-title":"A european randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (\u226416 years) low grade glioma \u2013 a final report","volume":"81","author":"Gnekow","year":"2017","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.ejca.2026.117450_bib6","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1200\/JCO.2011.36.6054","article-title":"Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the children\u2019s oncology group","volume":"30","author":"Ater","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.117450_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/neuonc\/noq178","article-title":"Survival and long-term health and cognitive outcomes after low-grade glioma","volume":"13","author":"Armstrong","year":"2011","journal-title":"Neuro-Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2026.117450_bib8","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1200\/JCO.2008.21.2738","article-title":"Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits","volume":"27","author":"Merchant","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.117450_bib9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00066-003-8104-0","article-title":"Current and future strategies in radiotherapy of childhood low-grade glioma of the brain: part ii: treatment-related late toxicity","volume":"179","author":"Kortmann","year":"2003","journal-title":"Strahlenther Onkol"},{"issue":"6","key":"10.1016\/j.ejca.2026.117450_bib10","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(14)71206-9","article-title":"Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies","volume":"16","author":"Northcott","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2026.117450_bib11","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00018-011-0898-9","article-title":"MAPK pathway activation in pilocytic astrocytoma","volume":"69","author":"Jones","year":"2012","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"10.1016\/j.ejca.2026.117450_bib12","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ng.2611","article-title":"Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.ejca.2026.117450_bib13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ng.2682","article-title":"Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.ejca.2026.117450_bib14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00401-018-1874-3","article-title":"Pediatric low-grade gliomas can be molecularly stratified for risk","volume":"136","author":"Yang","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117450_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40478-020-00902-z","article-title":"Pediatric low-grade glioma in the era of molecular diagnostics","volume":"8","author":"Ryall","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"9","key":"10.1016\/j.ejca.2026.117450_bib16","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/NEN.0b013e3181845622","article-title":"Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma","volume":"67","author":"Bar","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"issue":"21","key":"10.1016\/j.ejca.2026.117450_bib17","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1158\/0008-5472.CAN-08-2097","article-title":"Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas","volume":"68","author":"Jones","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2026.117450_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.117450_bib19","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117450_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40364-021-00281-0","article-title":"MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions","volume":"9","author":"Harder","year":"2021","journal-title":"Biomark Res"},{"issue":"_2","key":"10.1016\/j.ejca.2026.117450_bib21","doi-asserted-by":"crossref","first-page":"i114","DOI":"10.1093\/neuonc\/noy059.385","article-title":"LGG\u201144. A phase I dose escalation trial of the MEK1\/2 inhibitor MEK162 (binimetinib) in children with low\u2011grade gliomas and other RAS\/RAF pathway\u2011activated tumors","volume":"20","author":"Robison","year":"2018","journal-title":"Neuro\u2011Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.117450_bib22","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/neuonc\/noae274","article-title":"Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed\/refractory optic pathway glioma in the FIREFLY-1 trial","volume":"27","author":"Nysom","year":"2025","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.117450_bib23","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.22.01000","article-title":"Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600\u2013mutant low-grade glioma","volume":"41","author":"Bouffet","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.117450_bib24","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00280-016-2993-y","article-title":"Population pharmacokinetics and exposure\u2013response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma","volume":"77","author":"Ouellet","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.ejca.2026.117450_bib25","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S1470-2045(20)30064-4","article-title":"Response assessment in paediatric low-grade glioma: recommendations from the response assessment in pediatric neuro-oncology (RAPNO) working group","volume":"21","author":"Fangusaro","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.117450_bib26","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Bethesda (MD): US Department of Health and Human Services; 2017."},{"key":"10.1016\/j.ejca.2026.117450_bib27","doi-asserted-by":"crossref","unstructured":"WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards based on length\/height, weight and age. Acta Paediatr Suppl. 2006;450:76\u201385. doi:10.1111\/j.1651-2227.2006.tb02378.x.","DOI":"10.1111\/j.1651-2227.2006.tb02378.x"},{"key":"10.1016\/j.ejca.2026.117450_bib28","unstructured":"World Health Organization. WHO child growth standards: length\/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Geneva: World Health Organization; 2006. https:\/\/www.who.int\/publications\/i\/item\/924154693X."},{"issue":"1","key":"10.1016\/j.ejca.2026.117450_bib29","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","article-title":"A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01","volume":"19","author":"Perreault","year":"2019","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2026.117450_bib30","doi-asserted-by":"crossref","first-page":"e730","DOI":"10.1097\/MPH.0000000000001819","article-title":"Trametinib-based treatment of pediatric CNS tumors: a single institutional experience","volume":"42","author":"Paul","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.117450_bib31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11060-020-03640-3","article-title":"Response to trametinib treatment in progressive pediatric low-grade glioma patients","volume":"149","author":"Selt","year":"2020","journal-title":"J Neurooncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.117450_bib32","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/neuonc\/noaf065","article-title":"A phase 2 PBTC study of selumetinib for recurrent\/progressive pediatric low\u2011grade glioma: Strata 2, 5, and 6 with long\u2011term outcomes on strata 1, 3, and 4","volume":"27","author":"Banerjee","year":"2025","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117450_bib33","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","article-title":"A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01","volume":"19","author":"Perreault","year":"2019","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2026.117450_bib34","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.3390\/cancers13092010","article-title":"A phase 2 clinical trial of trametinib and low\u2011dose dabrafenib in patients with advanced pretreated NRASQ61R\/K\/L mutant melanoma (TraMel\u2011WT)","volume":"13","author":"Awada","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejca.2026.117450_bib35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-024-04896-9","article-title":"Endocrine effects of MEK and BRAF inhibitor therapy in paediatric patients: a tertiary centre experience","volume":"172","author":"Jalal","year":"2025","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2026.117450_bib36","article-title":"Type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma (pLGG): reversible decreases in growth velocity in the phase 2 FIREFLY-1 study","author":"Cassie","year":"2024","journal-title":"Am Soc Clin Oncol (ASCO) Annu Meet"},{"issue":"1","key":"10.1016\/j.ejca.2026.117450_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-025-04761-0","article-title":"Real-world pharmacokinetics of trametinib in pediatric low-grade glioma","volume":"95","author":"Pagnot","year":"2025","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926012323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926012323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:31:47Z","timestamp":1791660707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926012323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"alternative-id":["S0959804926012323"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117450","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117450","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117450"}}